Anti-secukinumab antibodies are antidrug antibodies (ADAs) developed in response to therapeutic administration of secukinumab, a human monoclonal antibody targeting interleukin-17A (IL-17A). Secukinumab is widely used to treat immune-mediated inflammatory diseases such as psoriasis, uveitis, rheumatoid arthritis, and ankylosing spondylitis. While it offers excellent efficacy in reducing chronic inflammation and normalizing skin histology, the immune system may, in some patients, recognize the biologic therapy as foreign and generate neutralizing or non-neutralizing antibodies against it.
The presence of anti-secukinumab antibodies, particularly neutralizing antibodies (NAbs), can compromise therapeutic effectiveness by inhibiting the drug’s binding to IL-17A, thereby restoring inflammatory pathways and reducing clinical response. Monitoring these antibodies in patient serum through validated immunoassays allows clinicians to assess potential loss of efficacy or adverse immune responses. Therapeutic drug monitoring (TDM) incorporating ADA testing supports dose optimization, therapy switching, or cessation decisions for non-responders or those experiencing reduced benefit over time.
In research settings, detection of anti-secukinumab antibodies helps evaluate the immunogenicity of the biologic in clinical trials and post-marketing surveillance. It also contributes to understanding patient variability in response to IL-17A-targeted therapies. As with other biologics, even minor manufacturing differences in biosimilar or subsequent versions may influence immunogenic profiles, making ADA tracking a critical part of pharmacovigilance and treatment refinement.
This product is manufactured in Turkey by Matriks Biotek.